Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 250568, 7 pages
http://dx.doi.org/10.1155/2008/250568
Review Article

Chondrosarcoma and Peroxisome Proliferator-Activated Receptor

1Department of Human Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
2Department of Orthopaedic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

Received 1 March 2008; Accepted 17 July 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 K. Nishida et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. H. Park, B. Breyer, and T.-C. He, “Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer,” Current Opinion in Oncology, vol. 13, no. 1, pp. 78–83, 2001. View at Publisher · View at Google Scholar
  2. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
  3. G. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000. View at Publisher · View at Google Scholar
  4. E.-Z. Amri, F. Bonino, G. Ailhaud, N. A. Abumrad, and P. A. Grimaldi, “Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors,” The Journal of Biological Chemistry, vol. 270, no. 5, pp. 2367–2371, 1995. View at Publisher · View at Google Scholar
  5. T. Lemberger, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology,” Annual Review of Cell and Developmental Biology, vol. 12, pp. 335–363, 1996. View at Publisher · View at Google Scholar · View at PubMed
  6. S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARS in health and disease,” Nature, vol. 405, no. 6785, pp. 421–424, 2000. View at Publisher · View at Google Scholar · View at PubMed
  7. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12,14, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995. View at Publisher · View at Google Scholar
  8. T. Wang, J. Xu, X. Yu, R. Yang, and Z. C. Han, “Peroxisome proliferator-activated receptor γ in malignant diseases,” Critical Reviews in Oncology/Hematology, vol. 58, no. 1, pp. 1–14, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. H. D. Dorfman and B. Czerniak, “Malignant cartilage tumors,” in Bone Tumors, pp. 353–440, Mosby, Saint Louis, Mo, USA, 1998. View at Google Scholar
  10. F. Bertoni, P. Bacchini, and P. C. Hogendoorn, “Chondrosarcoma,” in World Health Organaization Classification of Tumours: Pathology and Genetics, Tumours of Soft Tissue and Bone, C. D. M. Fletcher, K. K. Unni, and F. Mertens, Eds., IARC Press, Lyon, France, 2002. View at Google Scholar
  11. H. L. Evans, A. G. Ayala, and M. M. Romsdahl, “Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading,” Cancer, vol. 40, no. 2, pp. 818–831, 1977. View at Publisher · View at Google Scholar
  12. J. V. M. G. Bovée, A.-M. Cleton-Jansen, A. H. M. Taminiau, and P. C. W. Hogendoorn, “Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment,” The Lancet Oncology, vol. 6, no. 8, pp. 599–607, 2005. View at Publisher · View at Google Scholar · View at PubMed
  13. K. K. Unni, “Chondrosarcoma (primary, secondary, dedifferentiated, and clear cell),” in Dahlin's Bone Tumors: General Aspects and Data on 11,087 Cases, pp. 71–108, Lippincott-Raven, Philadelphia, Pa, USA, 1996. View at Google Scholar
  14. T. Ozaki, N. Lindner, A. Hillmann, R. Rödl, S. Blasius, and W. Winkelmann, “Influence of intralesional surgery on treatment outcome of chondrosarcoma,” Cancer, vol. 77, no. 7, pp. 1292–1297, 1996. View at Publisher · View at Google Scholar
  15. V. O. Lewis, “What's new in musculoskeletal oncology,” The Journal of Bone & Joint Surgery, vol. 89, no. 6, pp. 1399–1407, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. R. M. Terek, “Recent advances in the basic science of chondrosarcoma,” Orthopedic Clinics of North America, vol. 37, no. 1, pp. 9–14, 2006. View at Publisher · View at Google Scholar · View at PubMed
  17. T. Kunisada, J. M. Moseley, J. L. Slavin, T. J. Martin, and P. F. M. Choong, “Co-expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in cartilaginous tumours: a marker for malignancy?,” Pathology, vol. 34, no. 2, pp. 133–137, 2002. View at Publisher · View at Google Scholar
  18. T. Shakunaga, T. Ozaki, N. Ohara et al., “Expression of connective tissue growth factor in cartilaginous tumors,” Cancer, vol. 89, no. 7, pp. 1466–1473, 2000. View at Publisher · View at Google Scholar
  19. J. V. M. G. Bovée, L. J. C. M. van den Broek, A.-M. Cleton-Jansen, and P. C. W. Hogendoorn, “Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma,” Laboratory Investigation, vol. 80, no. 12, pp. 1925–1933, 2000. View at Publisher · View at Google Scholar
  20. M. Amling, M. Pösl, M. W. Hentz, M. Priemel, and G. Delling, “PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors,” Verhandlungen der Deutschen Gesellschaft für Pathologie, vol. 82, pp. 160–169, 1998. View at Google Scholar
  21. R. M. Terek, J. H. Healey, P. Garin-Chesa, S. Mak, A. Huvos, and A. P. Albino, “p53 mutations in chondrosarcoma,” Diagnostic Molecular Pathology, vol. 7, no. 1, pp. 51–56, 1998. View at Publisher · View at Google Scholar
  22. B. Coughlan, A. Feliz, T. Ishida, B. Czerniak, and H. D. Dorfman, “p53 expression and DNA ploidy of cartilage lesions,” Human Pathology, vol. 26, no. 6, pp. 620–624, 1995. View at Publisher · View at Google Scholar
  23. I. Sulzbacher, P. Birner, K. Trieb, M. Mühlbauer, S. Lang, and A. Chott, “Platelet-derived growth factor-α receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome,” The American Journal of Surgical Pathology, vol. 25, no. 12, pp. 1520–1527, 2001. View at Publisher · View at Google Scholar
  24. T. Furumatsu, K. Nishida, A. Kawai, M. Namba, H. Inoue, and Y. Ninomiya, “Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth,” International Journal of Cancer, vol. 97, no. 3, pp. 313–322, 2002. View at Publisher · View at Google Scholar · View at PubMed
  25. R. N. Rosier, R. J. O'Keefe, L. A. Teot et al., “P-glycoprotein expression in cartilaginous tumors,” Journal of Surgical Oncology, vol. 65, no. 2, pp. 95–105, 1997. View at Publisher · View at Google Scholar
  26. M. Takigawa, H.-O. Pan, M. Enomoto et al., “A clonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor,” Anticancer Research, vol. 10, no. 2A, pp. 311–315, 1990. View at Google Scholar
  27. T. Chano, H. Okabe, Y. Saeki, M. Ishizawa, K. Matsumoto, and S. Hukuda, “Characterization of a newly established human chondrosarcoma cell line, CS-OKB,” Virchows Archiv, vol. 432, no. 6, pp. 529–534, 1998. View at Publisher · View at Google Scholar
  28. H. Chansky, J. R. Robbins, S. Cha, W. H. Raskind, E. U. Conrad, and L. J. Sandell, “Expression of cartilage extracellular matrix and potential regulatory genes in a new human chondrosarcoma cell line,” Journal of Orthopaedic Research, vol. 16, no. 5, pp. 521–530, 1998. View at Publisher · View at Google Scholar · View at PubMed
  29. R. Gil-Benso, C. Lopez-Gines, J. A. López-Guerrero et al., “Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: comparative histologic and genetic studies with its tumor of origin,” Laboratory Investigation, vol. 83, no. 6, pp. 877–887, 2003. View at Google Scholar
  30. I. Kudawara, N. Araki, A. Myoui, Y. Kato, A. Uchida, and H. Yoshikawa, “New cell lines with chondrocytic phenotypes from human chondrosarcoma,” Virchows Archiv, vol. 444, no. 6, pp. 577–586, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. T. Kunisada, M. Miyazaki, K. Mihara et al., “A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation,” International Journal of Cancer, vol. 77, no. 6, pp. 854–859, 1998. View at Publisher · View at Google Scholar
  32. K. Demircan, S. Hirohata, K. Nishida et al., “ADAMTS-9 is synergistically induced by interleukin-1β and tumor necrosis factor α in OUMS-27 chondrosarcoma cells and in human chondrocytes,” Arthritis & Rheumatism, vol. 52, no. 5, pp. 1451–1460, 2005. View at Publisher · View at Google Scholar · View at PubMed
  33. T. Furumatsu, N. Yamaguchi, K. Nishida et al., “Endostatin inhibits adhesion of endothelial cells to collagen I viaα2β1 integrin, a possible cause of prevention of chondrosarcoma growth,” The Journal of Biochemistry, vol. 131, no. 4, pp. 619–626, 2002. View at Google Scholar
  34. T. Hayami, C. Shukunami, K. Mitsui et al., “Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo,” FEBS Letters, vol. 458, no. 3, pp. 436–440, 1999. View at Publisher · View at Google Scholar
  35. S. Subramanian, R. B. West, R. J. Marinelli et al., “The gene expression profile of extraskeletal myxoid chondrosarcoma,” The Journal of Pathology, vol. 206, no. 4, pp. 433–444, 2005. View at Publisher · View at Google Scholar · View at PubMed
  36. K. Nishida, T. Furumatsu, I. Takada et al., “Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-γ,” British Journal of Cancer, vol. 86, no. 8, pp. 1303–1309, 2002. View at Publisher · View at Google Scholar · View at PubMed
  37. Z.-N. Shen, K. Nishida, H. Doi et al., “Suppression of chondrosarcoma cells by 15-deoxy-Δ12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21,” Biochemical and Biophysical Research Communications, vol. 328, no. 2, pp. 375–382, 2005. View at Publisher · View at Google Scholar · View at PubMed
  38. Y. Tsujimoto, “Cell death regulation by the Bcl-2 protein family in the mitochondria,” Journal of Cellular Physiology, vol. 195, no. 2, pp. 158–167, 2003. View at Publisher · View at Google Scholar · View at PubMed
  39. F. Yang, Z. Zhang, D. Xin et al., “Peroxisome proliferator-activated receptor γ ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines,” Acta Pharmacologica Sinica, vol. 26, no. 6, pp. 753–761, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. M. Röpke, C. Boltze, H. W. Neumann, A. Roessner, and R. Schneider-Stock, “Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma,” Pathology, Research and Practice, vol. 199, no. 6, pp. 437–444, 2003. View at Publisher · View at Google Scholar
  41. M. Esteller, “Aberrant DNA methylation as a cancer-inducing mechanism,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 629–656, 2005. View at Publisher · View at Google Scholar · View at PubMed
  42. M. Esteller, “CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future,” Oncogene, vol. 21, no. 35, pp. 5427–5440, 2002. View at Publisher · View at Google Scholar · View at PubMed
  43. M. Esteller, M. F. Fraga, M. Guo et al., “DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis,” Human Molecular Genetics, vol. 10, no. 26, pp. 3001–3007, 2001. View at Publisher · View at Google Scholar
  44. H. M. van Beerendonk, L. B. Rozeman, A. H. M. Taminiau et al., “Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression,” The Journal of Pathology, vol. 202, no. 3, pp. 359–366, 2004. View at Publisher · View at Google Scholar · View at PubMed
  45. H. J. Grote, R. Schneider-Stock, W. Neumann, and A. Roessner, “Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma,” Virchows Archiv, vol. 436, no. 5, pp. 494–497, 2000. View at Publisher · View at Google Scholar
  46. J. Asp, L. Sangiorgi, S. E. Inerot et al., “Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues,” International Journal of Cancer, vol. 85, no. 6, pp. 782–786, 2000. View at Publisher · View at Google Scholar
  47. K. Hashimoto, R. T. Ethridge, and B. M. Evers, “Peroxisome proliferator-activated receptor γ ligand inhibits cell growth and invasion of human pancreatic cancer cells,” International Journal of Gastrointestinal Cancer, vol. 32, no. 1, pp. 7–22, 2002. View at Publisher · View at Google Scholar · View at PubMed
  48. N. G. Nikitakis, H. Siavash, C. Hebert, M. A. Reynolds, A. W. Hamburger, and J. J. Sauk, “15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells,” British Journal of Cancer, vol. 87, no. 12, pp. 1396–1403, 2002. View at Publisher · View at Google Scholar · View at PubMed
  49. C. Ward, I. Dransfield, J. Murray, S. N. Farrow, C. Haslett, and A. G. Rossi, “Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of IκBα degradation using a peroxisome proliferator-activated receptor-γ-independent mechanism,” The Journal of Immunology, vol. 168, no. 12, pp. 6232–6243, 2002. View at Google Scholar
  50. R. Butler, S. H. Mitchell, D. J. Tindall, and C. Y. F. Young, “Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2,” Cell Growth & Differentiation, vol. 11, no. 1, pp. 49–61, 2000. View at Google Scholar
  51. M. A. K. Rumi, H. Sato, S. Ishihara et al., “Peroxisome proliferator-activated receptor γ ligand-induced growth inhibition of human hepatocellular carcinoma,” British Journal of Cancer, vol. 84, no. 12, pp. 1640–1647, 2001. View at Publisher · View at Google Scholar · View at PubMed
  52. C. Wang, M. Fu, M. D'Amico et al., “Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-activated receptor γ-dependent repression of cyclin D1,” Molecular and Cellular Biology, vol. 21, no. 9, pp. 3057–3070, 2001. View at Publisher · View at Google Scholar · View at PubMed
  53. C. E. Clay, G. Atsumi, K. P. High, and F. H. Chilton, “Early de Novo gene expression is required for 15-deoxy-Δ12,14-prostaglandin J2-induced apoptosis in breast cancer cells,” The Journal of Biological Chemistry, vol. 276, no. 50, pp. 47131–47135, 2001. View at Publisher · View at Google Scholar · View at PubMed
  54. S. Laurora, S. Pizzimenti, F. Briatore et al., “Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 3, pp. 932–942, 2003. View at Publisher · View at Google Scholar · View at PubMed
  55. S. H. Chung, N. Onoda, T. Ishikawa et al., “Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells,” Japanese Journal of Cancer Research, vol. 93, no. 12, pp. 1358–1365, 2002. View at Google Scholar
  56. W. Motomura, N. Takahashi, M. Nagamine et al., “Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells,” International Journal of Cancer, vol. 108, no. 1, pp. 41–46, 2004. View at Publisher · View at Google Scholar · View at PubMed
  57. W. Motomura, T. Okumura, N. Takahashi, T. Obara, and Y. Kohgo, “Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells,” Cancer Research, vol. 60, no. 19, pp. 5558–5564, 2000. View at Google Scholar
  58. S. Takeuchi, T. Okumura, W. Motomura, M. Nagamine, N. Takahashi, and Y. Kohgo, “Troglitazone induces G1 arrest by p27Kip1 induction that is mediated by inhibition of proteasome in human gastric cancer cells,” Japanese Journal of Cancer Research, vol. 93, no. 7, pp. 774–782, 2002. View at Google Scholar
  59. R.F. Morrison and S.R. Farmer, “Role of PPAR in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis,” The Journal of Biological Chemistry, vol. 274, no. 24, pp. 17088–17097, 1999. View at Google Scholar
  60. J. A. Copland, L. A. Marlow, S. Kurakata et al., “Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1,” Oncogene, vol. 25, no. 16, pp. 2304–2317, 2006. View at Publisher · View at Google Scholar · View at PubMed
  61. S. Han, N. Sidell, P. B. Fisher, and J. Roman, “Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γ in human lung carcinoma cells,” Clinical Cancer Research, vol. 10, no. 6, pp. 1911–1919, 2004. View at Publisher · View at Google Scholar
  62. G. D. Demetri, C. D. M. Fletcher, E. Mueller et al., “Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3951–3956, 1999. View at Publisher · View at Google Scholar
  63. E. Mueller, M. Smith, P. Sarraf et al., “Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 10990–10995, 2000. View at Publisher · View at Google Scholar · View at PubMed
  64. G. Debrock, V. Vanhentenrijk, R. Sciot, M. Debiec-Rychter, R. Oyen, and A. Van Oosterom, “A phase II trial with rosiglitazone in liposarcoma patients,” British Journal of Cancer, vol. 89, no. 8, pp. 1409–1412, 2003. View at Publisher · View at Google Scholar · View at PubMed
  65. L. D. Yee, N. Williams, P. Wen et al., “Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers,” Clinical Cancer Research, vol. 13, no. 1, pp. 246–252, 2007. View at Publisher · View at Google Scholar · View at PubMed
  66. M. H. Kulke, G. D. Demetri, N. E. Sharpless et al., “A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer,” Cancer Journal, vol. 8, no. 5, pp. 395–399, 2002. View at Publisher · View at Google Scholar
  67. G. K. Schwartz, A. Weitzman, E. O'Reilly et al., “Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 23, no. 23, pp. 5365–5373, 2005. View at Publisher · View at Google Scholar · View at PubMed